Paul McKenzie, CSL Behring CEO
CSL Behring says uptake of hemophilia B gene therapy slower than expected
More than a year after launching the first-ever gene therapy for hemophilia B, CSL Behring revealed that it’s treated more than 12 patients so far …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
